Stallergenes' Oralair Grasses tablets gain German approval
This article was originally published in Scrip
Stallergenes’ sublingual desensitisation tablets Oralair Grasses have been approved in Germany for the treatment of moderate severe allergic rhinitis and rhino conjunctivitis caused by grass pollen.
You may also be interested in...
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.
GlaxoSmithKlineand Xenoporthave submitted an NDA to the US FDAfor the once-daily restless legs syndrome drug Solzira (gabapentin enacarbil extended-release tablets), previously known as GSK1838262 by GSK and XP13512 by Xenoport.